Abstract #4193

Dynamic Contrast-Enhanced MR Imaging for Early Detection of Vascular-Permeability Changes Following Combination Therapy with Anti-EGFR Antibody and Irinotecan in Orthotopic Pancreatic Tumor Xenografts: A Pilot Study

Hyunki Kim¹, Karri Folks¹, Lingling Guo², James George², Jeffrey Sellers³, Donald Buchsbaum⁴, Kurt Zinn¹

¹Radiology, University of Alabama at Birmingham, Birmingham, AL, USA; ²Surgery, University of Alabama at Birmingham, Birmingham, AL, USA; ³Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA; ⁴Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

DCE MR imaging was applied for pancreatic tumor xenografts implanted in SCID mice orthotopically, detecting a significant therapeutic response in 3 days after anti-EGFR antibody and irinotecan administration. The early Ktrans decrease responsive to therapy was well correlated with tumor-growth suppression and bioluminescence-signal decrease over the 6 days of treatment. Therefore, DCE-MRI may be a reasonable approach to determine individualized tumor response against anti-EGFR antibody and/or irinotecan in clinical trials.